A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy. | Synapse
January 25, 2026
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy.
Key Points
This research aims to create a model predicting how individual patients will respond to corticosteroid treatment for IgA nephropathy.
Conducted a secondary analysis of existing trial data
Developed a predictive model for response to methylprednisolone
Targeted corticosteroid treatment based on model outputs
Identified specific predictors for individual patient response to treatment
Demonstrated that some patients are more likely to benefit from corticosteroids
Enhanced targeting of treatment could improve patient outcomes
Abstract
We have generated a model that can predict individual patient response to methylprednisolone so that corticosteroids can be targeted to those most likely to benefit.